<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094067</url>
  </required_header>
  <id_info>
    <org_study_id>AC-051-207</org_study_id>
    <nct_id>NCT01094067</nct_id>
  </id_info>
  <brief_title>Tezosentan in Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Demonstrate That a Single Infusion of Tezosentan Has Minimal Effect on Blood Pressure in Patients With Pulmonary Arterial Hypertension, Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or a Combination of Both.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate&#xD;
      that a single infusion of tezosentan has minimal effect on blood pressure in patients with&#xD;
      pulmonary arterial hypertension, treated with endothelin receptor antagonists,&#xD;
      phosphodiesterase-5 inhibitors or a combination of both.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow recruitment, the study was prematurely discontinued.&#xD;
  </why_stopped>
  <start_date>September 1, 2010</start_date>
  <completion_date type="Actual">September 1, 2011</completion_date>
  <primary_completion_date type="Actual">December 1, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in supine SBP from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in mmHg</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in heart rate from Baseline to 30 minutes at each visit (Visit 1 and Visit 2) - in bpm</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo at visit 1, tezosentan at visit 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezosentan at visit 1, placebo at visit 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-050089</intervention_name>
    <description>5 mg/h intravenously, Tezosentan</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          1. Signed informed consent prior to initiation of any study-mandated procedure&#xD;
&#xD;
          2. Male and female patients 18 years of age or older&#xD;
&#xD;
          3. Patients with PAH according to one of the following subgroups of the Dana Point&#xD;
             Classification Group 1:&#xD;
&#xD;
               -  Idiopathic, or&#xD;
&#xD;
               -  Heritable, or&#xD;
&#xD;
               -  Associated with connective tissue disease&#xD;
&#xD;
          4. Documented hemodynamic diagnosis of PAH by right heart catheterization (not part of&#xD;
             study mandated procedures):&#xD;
&#xD;
               -  Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and&#xD;
&#xD;
               -  Resting mean pulmonary vascular resistance (PVR) ≥ 240 dyn•s•cm 5 and&#xD;
&#xD;
               -  Pulmonary capillary wedge pressure ≤ 15 mmHg&#xD;
&#xD;
          5. Modified NYHA functional class II-III&#xD;
&#xD;
          6. Patients on treatment with ERAs, PDE-5 inhibitors or a combination of both, if used&#xD;
             for at least 3 months prior to Visit 1 and dosing kept stable for at least 28 days&#xD;
             prior to Visit 1.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          1. Patients with PAH in Dana Point Classification Groups 2-5, and PAH Group 1 subgroups&#xD;
             not covered by inclusion criterion No. 3&#xD;
&#xD;
          2. Patients with sitting SBP &lt; 100 mmHg&#xD;
&#xD;
          3. Patients with sitting DBP &lt; 60 mmHg&#xD;
&#xD;
          4. Patients with body weight &lt; 50 kg (110 lbs)&#xD;
&#xD;
          5. Patients with clinically significantly elevated liver enzymes (AST, ALT and/or&#xD;
             alkaline phosphatase &gt; 3 times upper limit)&#xD;
&#xD;
          6. Patients with clinically significant chronic renal insufficiency (serum creatinine&#xD;
             &gt;2.5mg/dL / 221 µmol/L)&#xD;
&#xD;
          7. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)&#xD;
&#xD;
          8. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g.,&#xD;
             treprostinil, iloprost and beraprost) within 28 days of Visit 1&#xD;
&#xD;
          9. Patients who have received any investigational drugs within 28 days of Visit 1&#xD;
&#xD;
         10. Patients who have received cyclosporine A (CsA) or tacrolimus within 28 days of Visit&#xD;
             1&#xD;
&#xD;
         11. Psychotic, addictive or other disorder limiting the ability to provide informed&#xD;
             consent or to comply with the study&#xD;
&#xD;
         12. Life expectancy less than 12 months&#xD;
&#xD;
         13. Females who are lactating or pregnant (positive pre-treatment pregnancy tests) (serum&#xD;
             test at Screening and urine test on Visit 1 and 2) or females who are not using a&#xD;
             reliable method of birth control (failure rate less than 1% per year) during the study&#xD;
             and for at least one month after last administration of study drug&#xD;
&#xD;
         14. Known hypersensitivity to any of the excipients of the drug formulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Osaka</city>
        <zip>565-8865</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-Ku</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

